1. Home
  2. ATCH vs ENTO Comparison

ATCH vs ENTO Comparison

Compare ATCH & ENTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATCH
  • ENTO
  • Stock Information
  • Founded
  • ATCH 2022
  • ENTO 2014
  • Country
  • ATCH United States
  • ENTO United States
  • Employees
  • ATCH N/A
  • ENTO N/A
  • Industry
  • ATCH
  • ENTO Biotechnology: Pharmaceutical Preparations
  • Sector
  • ATCH
  • ENTO Health Care
  • Exchange
  • ATCH Nasdaq
  • ENTO Nasdaq
  • Market Cap
  • ATCH 2.5M
  • ENTO 2.3M
  • IPO Year
  • ATCH N/A
  • ENTO 2016
  • Fundamental
  • Price
  • ATCH $0.18
  • ENTO $0.36
  • Analyst Decision
  • ATCH
  • ENTO
  • Analyst Count
  • ATCH 0
  • ENTO 0
  • Target Price
  • ATCH N/A
  • ENTO N/A
  • AVG Volume (30 Days)
  • ATCH 30.3M
  • ENTO 155.9K
  • Earning Date
  • ATCH 08-27-2025
  • ENTO 05-15-2025
  • Dividend Yield
  • ATCH N/A
  • ENTO N/A
  • EPS Growth
  • ATCH N/A
  • ENTO N/A
  • EPS
  • ATCH N/A
  • ENTO N/A
  • Revenue
  • ATCH $14,825,966.00
  • ENTO N/A
  • Revenue This Year
  • ATCH N/A
  • ENTO N/A
  • Revenue Next Year
  • ATCH N/A
  • ENTO N/A
  • P/E Ratio
  • ATCH N/A
  • ENTO N/A
  • Revenue Growth
  • ATCH 1066.77
  • ENTO N/A
  • 52 Week Low
  • ATCH $0.14
  • ENTO $0.19
  • 52 Week High
  • ATCH $26.94
  • ENTO $0.93
  • Technical
  • Relative Strength Index (RSI)
  • ATCH 46.62
  • ENTO 33.79
  • Support Level
  • ATCH $0.17
  • ENTO $0.44
  • Resistance Level
  • ATCH $0.22
  • ENTO $0.46
  • Average True Range (ATR)
  • ATCH 0.03
  • ENTO 0.04
  • MACD
  • ATCH 0.00
  • ENTO -0.01
  • Stochastic Oscillator
  • ATCH 22.77
  • ENTO 3.27

About ATCH AtlasClear Holdings Inc. Common Stock

AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and innovative financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.

About ENTO Entero Therapeutics Inc. Common Stock

Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: